Kidney transplant monitoring by anti donor specific antibodies.
Donor-specific anti-HLA antibodies were studied by cytotoxicity crossmatching (CTXM) and flow cytometry crossmatching (FCXM) in 117 kidney transplant candidates; the same study was carried out in 33 cadaver-donor kidney recipients, during the first 3 post-transplant months, for which donor cells were available. Pre-transport evaluation showed that 82.9% of subjects were CTXM negative/FCXM negative, 6.8% of patients were positive in both tests, and 10.3% were CTXM negative/FCCM positive. Post-transplant monitoring for donor-specific antibodies (Abs-DS) showed that nine recipients (27.3%) were FCXM positive; six of them were IgG+ and three IgM+. In comparing these results with the clinical course, a significant association between FCXM IgG+ and rejection episodes was observed (P < 0.01).
Torlone
N
N
Clinica Chirurgica-II University of Rome, Rome, Italy.
Piazza
A
A
Valeri
M
M
Monaco
P I
PI
Provenzani
L
L
Poggi
E
E
Adorno
D
D
Casciani
C U
CU
D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D005434:Flow Cytometry / Q000379:methods; D006650:Histocompatibility Testing; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007518:Isoantibodies / Q000097:blood*; D016030:Kidney Transplantation / Q000276:immunology*; D015166:Monitoring, Immunologic; D012189:Retrospective Studies; D013997:Time Factors
D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007518:Isoantibodies